Jeff Albers and Kate Haviland (Brad Bahner Photography/PR Newswire)

Blue­print­'s long­time CEO pre­pares to step down as biotech rev­els in new Ay­vak­it launch, pipeline ex­pan­sion

Af­ter a busy 2021 brought Blue­print Med­i­cines its fourth FDA ap­proval, the com­pa­ny is kick­ing off the new year with plans to shake up its C-suite.

Jeff Al­bers, Blue­print’s CEO for the past eight years, will be step­ping down April 4 and tran­si­tion­ing to the ex­ec­u­tive chair­man po­si­tion, the biotech an­nounced Wednes­day morn­ing. He will be re­placed by COO Kate Hav­i­land, who moves in­to both the chief ex­ec­u­tive and pres­i­dent roles. Christi­na Rossi al­so nabs a pro­mo­tion from chief com­mer­cial of­fi­cer to COO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.